Lilly Unit: Positive Phase 1/2 Data for Investigational Gene Therapy for Genetic Hearing Loss

 Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss

AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF)

https://www.biospace.com/article/releases/positive-phase-1-2-clinical-trial-data-for-an-investigational-gene-therapy-for-genetic-hearing-loss-to-be-presented-at-the-association-for-research-in-otolaryngology-2024-midwinter-meeting/